Targeting FLT3 kinase in acute myelogeneous leukemia: Progress, perils, and prospects

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations

Abstract

Activating mutations of the FLT3 receptor tyrosine kinase are the most common recurring genetic abnormality in acute myelogenous leukemia (AM). Inhibition of FLT3 kinase activity by small molecule inhibitors has been proposed as a novel therapeutic approach AML. The pre-clinical and clinical development of candidate FLT3 inhibitors will be reviewed.

Original languageEnglish (US)
Pages (from-to)255-271
Number of pages17
JournalMini-Reviews in Medicinal Chemistry
Volume4
Issue number3
DOIs
StatePublished - Mar 1 2004

Keywords

  • AML
  • FLT3
  • KIT
  • Kinase inhibitor
  • PDGFR
  • Tyrosine kinase

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Cancer Research

Fingerprint

Dive into the research topics of 'Targeting FLT3 kinase in acute myelogeneous leukemia: Progress, perils, and prospects'. Together they form a unique fingerprint.

Cite this